$CUE

B.Riley reiterated a Buy rating and $83.00 price target on Cue Biopharma (NASDAQ:CUE) after an event on IgE-mediated diseases. The stock is down 21% this week but up 326% in six months. Analysts highlighted positive data on CUE-221 and its potential compared to omalizumab. The firm sees upcoming data disclosures as key catalysts. Cue Biopharma recently raised $50M and appointed a new Chief Medical Officer. Analysts view the stock as undervalued with targets up to $115.

Cue Biopharma (CUE) reported positive Phase 2 results for CUE-221 in treating chronic hives, with 54% of patients achieving complete hive resolution vs. 11% on placebo. The drug showed sustained relief 12 weeks post-treatment, with 60% of patients in the highest-dose group remaining hive-free. No serious adverse events were reported. The company plans a Phase 2b/3 study and has $67.4M in cash after recent financing.

Cue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling stu

U.S. stock futures rose on Monday, driven by gains in crypto-linked and AI-related stocks. Bitcoin surged 5.1% to $84,435.90, boosting MicroStrategy, Coinbase, and Robinhood. AI stocks like Intel, Marvell, and Meta also climbed. Warner Bros. Discovery and Paramount gained on merger talks. Companies tied to Greenland, Accenture, Cue Biopharma, SVRN, and Alamar Biosciences saw significant premarket moves.

Cue Biopharma (CUE) stock surged 41.6% in pre-market trading after positive Phase 2 trial results for CUE-221, its anti-IgE monoclonal antibody, in treating chronic spontaneous urticaria. The trial met primary and secondary endpoints with statistical significance and a favorable safety profile. The data suggests CUE-221 may offer advantages over the current standard of care, omalizumab (XOLAIR®). B. Riley Securities initiated coverage with a Buy rating.

Cue Biopharma (CUE) reported positive Phase 2a results for CUE-221 in treating chronic hives, meeting primary and key secondary endpoints. The study showed significant improvement in hive resolution compared to placebo. The company plans to advance to Phase 2b/3 trials. CUE stock rose 7.94% in after-hours trading.

aTyr (LIFE) appointed Brandon Yaras as CFO. City Therapeutics, Cue Biopharma (CUE), Longeveron (LGVN), Olema Oncology (OLEM), and Stuart Therapeutics made CFO appointments. Sanofi (SNY) expanded its CFO's role to include business operations and M&A.

Ray Sumita (Chief Legal Compliance Officer) sold 8,829 shares of Cue Biopharma, Inc. (CUE) at an average of $30.09 ($29.37–$31.13, $0.27M total) across 3 trades on 2026-08-13.

Meluzio Michael Vincent (VP, Prin. Accounting Officer) sold 5,628 shares of Cue Biopharma, Inc. (CUE) at an average of $30.09 ($29.37–$31.13, $0.17M total) across 3 trades on 2026-08-13.

Lin Shao-Lee (Chief Executive Officer) sold 58,258 shares of Cue Biopharma, Inc. (CUE) at an average of $27.58 ($26.99–$29.48, $1.61M total) across 5 trades over 2026-08-12 to 2026-08-13.